Acquisition deepens Revvity Signals’ presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions
Revvity, Inc. announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The transaction is expected to close late in Q4 2025.
Health Technology Insights: Organon to Sell JADA System to Laborie for $465Million
Revvity, Inc., today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences.
ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows. Its industry-leading tools help scientists identify and characterize molecules, monitor purity and quality, and deliver robust production processes. Together, Revvity Signals and ACD/Labs will provide comprehensive support across the scientific workflow—from discovery and development to scale-up and manufacturing— giving scientists the ability to interpret, manage, and act on complex data with greater speed and confidence.
Health Technology Insights: Fresenius Kabi Recalls Famotidine Injection Lots
ACD/Labs’ industry-leading tools include:
- Spectrus Platform: advanced spectral analysis
- Percepta Platform: AI-driven molecular property and ADMET prediction
- Other specialized applications: parallel and high-throughput experimentation (Katalyst D2D), pharmaceutical chemistry, manufacturing, and controls decision support (Luminata), and enterprise analytical data management (ADMS)
“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution,” said Kevin Willoe, president of Revvity Signals Software. “This acquisition adds meaningful value to our portfolio and reinforces the importance of analytical sciences as a driver of innovation across disciplines.”
“For more than three decades, our scientists, informaticians, and software developers have been recognized as leaders in analytical and chemical intelligence,” said Daria Thorp, president and CEO of ACD/Labs. “Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software. Together, we will expand the reach of our technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.”
Health Technology Insights: FillPoint Health Partners with Noble to Boost Patient Care
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
